Skip to content
Screener

Net Income at other companies

Arrowhead Research logo
Arrowhead ResearchARWR
-$132.73M-136%
PTC Therapeutics logo
PTC TherapeuticsPTCT
-$2.81M-100%
Assembly Biosciences logo
Assembly BiosciencesASMB
-$3.86M+62.2%
Arbutus Biopharma Corporation logo
Arbutus Biopharma CorporationABUS
-$5.14M-304%
Wave Life Sciences logo
Wave Life SciencesWVE
-$69.36M-37.4%
Intellia Therapeutics logo
Intellia TherapeuticsNTLA
-$106.63M-5.3%

Other financials

Income statement

See full
Revenue$1.3B+66.9%
Gross profit$992.7M+57.2%
Operating income$231.4M+1,529%
EPS (diluted)$1.21+337%

Balance sheet

See full
Cash & equivalents$1.7B+53.2%
Total debt$256.4M-5.2%
Total equity$1.4B+440%
Total assets$5.6B+21.7%

Cash flow

See full
Operating cash flow$326.7M+113%
CapEx$34.7M+143%
Free cash flow$292.0M+109%

Valuation

See full
Market cap$31.98B-46.3%
Enterprise value$30.53B-48.0%
P/E43.6×
P/S6.7×-17.5×

Profitability

See full
Gross margin79.8%-4.1pp
Operating margin20.8%+16.5pp
Net margin15.3%+10.7pp
FCF margin16.5%+14.8pp

Returns & leverage

See full
Return on equity91.4%
Debt / equity0.2×-0.9×
Current ratio3.1×+0.3×

Where this comes from

Reported directly by Alnylam Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The source filing: Alnylam Pharmaceuticals’s 10-Q, filed July 30, 2026.

Filed
Jul 30, 2026, 8:11 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001178670-26-000062
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Total other expense, net(53,635)(25,110)(100,618)(45,555)
Income (loss) before income taxes177,806(41,309)399,459(43,677)
Provision for income taxes(13,312)(30,919)(28,974)(46,802)
Net income (loss)$164,494$(72,228)$370,485$(90,479)
Net income (loss) per common share — basic$1.23$(0.55)$2.78$(0.70)
Net income (loss) per common share — diluted$1.21$(0.55)$2.71$(0.70)
Weighted-average common shares — basic133,606130,628133,244130,155
Weighted-average common shares — diluted138,281130,628138,249130,155

Cover / Front Matter

FAQ

What is Alnylam Pharmaceuticals's net income?
Alnylam Pharmaceuticals (ALNY) reported net income of $164.49M in Q2 2026.
How has Alnylam Pharmaceuticals's net income changed year-over-year?
Alnylam Pharmaceuticals's net income increased by 348.2% year-over-year, from -$66.28M to $164.49M.
What is the long-term trend for Alnylam Pharmaceuticals's net income?
Over 4 years (2021 to 2025), Alnylam Pharmaceuticals's net income has grown at a -24.4% compound annual growth rate (CAGR), from -$852.82M to $278.1M.
What does net income mean?
The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.

Ask your AI about Alnylam Pharmaceuticals's net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude